Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 13, 2017 – The FDA approved Allergan’s Saphris (asenapine) for maintenance monotherapy treatment of bipolar I disorder in adults.
Download PDF
Return to publications
